Details for Patent: 9,950,069

Which drugs does patent 9,950,069 protect, and when does it expire?

Patent 9,950,069 protects JELMYTO and is included in one NDA.

This patent has nine patent family members in six countries.

Summary for Patent: 9,950,069

Title:	Material and method for treating internal cavities
Abstract:	A hydrophilic biocompatible sustained-release material is disclosed. The material comprises amounts of Pluronic F-127, PEG-400, HPMC and water, effective to produce a composition of sufficiently low viscosity at room temperature to be injectable into an internal body cavity via a tube inserted within a urinary catheter. At body temperature, the material exhibits a much higher viscosity and will stably adhere to the internal surface of a body cavity. As the material dissolves, a therapeutic agent incorporated therein is slowly released to the body cavity, while the material itself is excreted from the body.
Inventor(s):	Holzer; Asher (Raanana, IL), Daniel; Dorit (Raanana, IL), Mullerad; Michael (Tel Aviv, IL), De La Zerda; Jaime (Haifa, IL), Shpolansky; Uri (Pardes Hana, IL), Malchi; Nadav (Pardes Hanna-Karkur, IL), Dollberg; Yosh (Raanana, IL), Tal; Dor (Hadera, IL), Yavin; Yossi (Mikhmoret, IL), Konorty; Marina (Hertzyla, IL)
Assignee:	UROGEN PHARMA LTD. (Raanana, IL)
Application Number:	15/366,256
Patent Claim Types: see list of patent claims	Use; Composition; Compound; Dosage form;

Drugs Protected by US Patent 9,950,069

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Urogen Pharma	JELMYTO	mitomycin	POWDER;PYELOCALYCEAL	211728-001	Apr 15, 2020		RX	Yes	Yes			Y

International Family Members for US Patent 9,950,069

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Germany	212011100034
Denmark	2525777
European Patent Office	2525777
European Patent Office	2734187
Spain	2732150